G
Galapagos NV (GLPG)
NMS – Real vaqt narxi. Valyuta: USD
27.73
+27.73 (0.00%)
Yopilishda: May 7, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
27.73
+27.73 (0.00%)
Yopilishda: May 7, 2026, 4:00 PM EDT
Galapagos NV, biotexnologiya kompaniyasi, asosan Qo'shma Shtatlar va Yevropada onkologiya va immunologiyaga qaratilgan dori-darmonlarni ishlab chiqadi. Kompaniyaning mahsulotlari qatoriga dermatomiyozit va tizimli qizil yug'richda 2-bosqichli klinik sinovdan o'tayotgan GLPG3667; nuqtada ishlab chiqarilgan CD19 CAR-T mahsuloti nomzodi GLPG5101, hozirda qaytalangan/refrakter non-Hodgkin limfomasida 1/2-bosqich sinovdan o'tmoqda; va nuqtada ishlab chiqarilgan BCMA CAR-T mahsuloti nomzodi GLPG5301, hozirda qaytalangan/refrakter ko'p miyelomada 1/2-bosqich sinovdan o'tmoqda kiradi. Kompaniyaning Gilead Sciences, Inc. bilan hamkorlik shartnomalari mavjud. Kompaniya 1999 yilda tashkil etilgan va shtab-kvartirasi Belgiya, Mechelen shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | Head of Investor Relations |
| Dr. Jeevan Shetty | Head of Clinical Development Oncology |
| Marieke Vermeersch | Head of Corporate Communication |
| Mr. Aaron L. Cox | Chief Financial Officer |
| Mr. Fred W. Blakeslee II | Executive VP & General Counsel |
| Mr. Henry Gosebruch | CEO & Executive Director |
| Ms. Annelies Missotten | Executive Officer |
| Ms. Ellen Van Der Aar | Head of Development |
| Ms. Tania Philipp | Chief Human Resources Officer |
| Ruiz Astigarraga | Head of Manufacturing Cell Therapy |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 6-K | f6k_050626.htm |
| 2026-04-29 | 6-K | tm2612973d1_6k.htm |
| 2026-03-31 | 6-K | d927249d6k.htm |
| 2026-03-30 | 6-K | d54917d6k.htm |
| 2026-03-26 | 20-F | glpg-20251231x20f.htm |
| 2026-03-24 | 6-K | f6k_032326.htm |
| 2026-03-17 | 6-K | f6k_031726.htm |
| 2026-03-10 | 6-K | f6k_031026.htm |
| 2026-03-06 | 6-K | f6k_030626.htm |
| 2026-03-05 | 6-K | f6k_030526.htm |